J&J sues GlaxoSmithKline over Flonase ads, CDC report finds patients with invasive cancer are living for five years or longer have diagnosis, and Bristol-Myers Squibb resubmits its HCV treatment.
Smartphones drove network traffic.
The Trustworthy Accountability of National Advertisers launched its naming-names initiative in November, but the list is empty.
23andMe is back in the DTC game; Sanofi has named its new CEO; drug companies are contemplating a pay-for-performance sales model.
FDA posted a revised draft guidance document on its brief summary and adequate directions for use concerning risk information in DTC print ads to reflect "recent social science research."
The list of objections by the Office of Prescription Drug Promotion, which oversees medical advertising, is a familiar one, and includes concerns such as claims that go beyond the approved indication.
FDA's latest guidance says it is ok to reduce the amount of risk information in print ads, Google amplifies the health information it will serve up with searches and HBO's John Oliver takes on pharmaceutical marketing.
Tina Fascetti is the mid-sized agency's new Chief Creative Officer. CEO Matt Brown (and ICC Lowe alum) tells MM&M the new Guidemark is just getting started.
The FDA is looking into whether abbreviated risk information is a good idea for DTC.
MAHF 2015 Heritage Ad Awards will be given to campaigns for Bentyl, Hytrin and Navane
With the purchase of Olson Communications, the agency aims to serve clients eager for expertise from outside the healthcare industry.
The Austin agency says it beat out FCB, Ogilvy CommonHealth, GSW Worldwide and H4B Chelsea for the work.
The London healthcare brand and research agency will be part of Omnicom's DAS Group.
The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.
The bad-ad watchdog says the promotional website for the weight-loss medication Suprenza leaves out too much information.
The regulator's latest study will use eye-tracking tools.
The advertising watchdog gave drugmaker Alvogen 15 days to make amends.
The Omnicom-Publicis deal may have been scuttled, but the hunger for deals remains.
The company said it used "inappropriate expressions" in promotions of a blood pressure medication.
The National Association of Boards of Pharmacy says about 97% of surveyed pharmacy sites fail to comply with laws.
The reason: Diovan.
A consumer survey will shape the regulator's position.
Canada's Office of the Privacy Commissioner says the search giant failed to protect what qualifies as sensitive user information.
A month after UBM Canon closed the B2B magazine, marketing firm Outcomes LLC announced its return to twice-a-year publication.
The agency says outlets need to rethink running ads that make false claims.
The Health Ministry alleges Novartis exaggerated advertising for its blood pressure drug Diovan.
Our year-end list captures the 10 that sparked heaviest interest.
Lobbying groups say the ad tax draft proposal could wreak havoc throughout the ad industry and its partners, such as publishers and broadcasters, if it were to go through.
Chronic disease patients seek online support and information, and show little love for branded websites.
An organ-donation campaign with a Brazilian football tie-in, and a UK managed-access company's series of documentary films, took top honors.
Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.
- US pharma market value projected to be $550 billion in five years
- Lawmakers propose allowing pharma companies to share some off-label information
- Biosimilar uptake will require companies to tell a trustworthy backstory
- Everyday Health buys rare-disease agency Cambridge BioMarketing
- Apple's ResearchKit: Five Guidelines for Pharma